164 related articles for article (PubMed ID: 35759195)
21. Design of pyrido[2,3-d]pyrimidin-7-one inhibitors of receptor interacting protein kinase-2 (RIPK2) and nucleotide-binding oligomerization domain (NOD) cell signaling.
Nikhar S; Siokas I; Schlicher L; Lee S; Gyrd-Hansen M; Degterev A; Cuny GD
Eur J Med Chem; 2021 Apr; 215():113252. PubMed ID: 33601309
[TBL] [Abstract][Full Text] [Related]
22. RIPK2 NODs to XIAP and IBD.
Topal Y; Gyrd-Hansen M
Semin Cell Dev Biol; 2021 Jan; 109():144-150. PubMed ID: 32631784
[TBL] [Abstract][Full Text] [Related]
23. Role of nucleotide-binding oligomerization domain 1 (NOD1) and its variants in human cytomegalovirus control in vitro and in vivo.
Fan YH; Roy S; Mukhopadhyay R; Kapoor A; Duggal P; Wojcik GL; Pass RF; Arav-Boger R
Proc Natl Acad Sci U S A; 2016 Nov; 113(48):E7818-E7827. PubMed ID: 27856764
[TBL] [Abstract][Full Text] [Related]
24. Immune modulating effects of receptor interacting protein 2 (RIP2) in autoinflammation and immunity.
Hofmann SR; Girschick L; Stein R; Schulze F
Clin Immunol; 2021 Feb; 223():108648. PubMed ID: 33310070
[TBL] [Abstract][Full Text] [Related]
25. CARD4/Nod1 mediates NF-kappaB and JNK activation by invasive Shigella flexneri.
Girardin SE; Tournebize R; Mavris M; Page AL; Li X; Stark GR; Bertin J; DiStefano PS; Yaniv M; Sansonetti PJ; Philpott DJ
EMBO Rep; 2001 Aug; 2(8):736-42. PubMed ID: 11463746
[TBL] [Abstract][Full Text] [Related]
26. Inflammatory Signaling by NOD-RIPK2 Is Inhibited by Clinically Relevant Type II Kinase Inhibitors.
Canning P; Ruan Q; Schwerd T; Hrdinka M; Maki JL; Saleh D; Suebsuwong C; Ray S; Brennan PE; Cuny GD; Uhlig HH; Gyrd-Hansen M; Degterev A; Bullock AN
Chem Biol; 2015 Sep; 22(9):1174-84. PubMed ID: 26320862
[TBL] [Abstract][Full Text] [Related]
27. Tyrosine kinase inhibitors of Ripk2 attenuate bacterial cell wall-mediated lipolysis, inflammation and dysglycemia.
Duggan BM; Foley KP; Henriksbo BD; Cavallari JF; Tamrakar AK; Schertzer JD
Sci Rep; 2017 May; 7(1):1578. PubMed ID: 28484277
[TBL] [Abstract][Full Text] [Related]
28. Engagement of nucleotide-binding oligomerization domain-containing protein 1 (NOD1) by receptor-interacting protein 2 (RIP2) is insufficient for signal transduction.
Mayle S; Boyle JP; Sekine E; Zurek B; Kufer TA; Monie TP
J Biol Chem; 2014 Aug; 289(33):22900-22914. PubMed ID: 24958724
[TBL] [Abstract][Full Text] [Related]
29. Innate Immune Nod1/RIP2 Signaling Is Essential for Cardiac Hypertrophy but Requires Mitochondrial Antiviral Signaling Protein for Signal Transductions and Energy Balance.
Lin HB; Naito K; Oh Y; Farber G; Kanaan G; Valaperti A; Dawood F; Zhang L; Li GH; Smyth D; Moon M; Liu Y; Liang W; Rotstein B; Philpott DJ; Kim KH; Harper ME; Liu PP
Circulation; 2020 Dec; 142(23):2240-2258. PubMed ID: 33070627
[TBL] [Abstract][Full Text] [Related]
30. RIPK2 as a New Therapeutic Target in Inflammatory Bowel Diseases.
Honjo H; Watanabe T; Kamata K; Minaga K; Kudo M
Front Pharmacol; 2021; 12():650403. PubMed ID: 33935757
[TBL] [Abstract][Full Text] [Related]
31. In vivo inhibition of RIPK2 kinase alleviates inflammatory disease.
Tigno-Aranjuez JT; Benderitter P; Rombouts F; Deroose F; Bai X; Mattioli B; Cominelli F; Pizarro TT; Hoflack J; Abbott DW
J Biol Chem; 2014 Oct; 289(43):29651-64. PubMed ID: 25213858
[TBL] [Abstract][Full Text] [Related]
32. NOD1 cooperates with HAX-1 to promote cell migration in a RIPK2- and NF-ĸB-independent manner.
Hezinger L; Bauer S; Ellwanger K; Piotrowsky A; Biber F; Venturelli S; Kufer TA
FEBS J; 2023 Nov; 290(22):5295-5312. PubMed ID: 37488967
[TBL] [Abstract][Full Text] [Related]
33. Fusobacterium nucleatum promotes esophageal squamous cell carcinoma progression via the NOD1/RIPK2/NF-κB pathway.
Nomoto D; Baba Y; Liu Y; Tsutsuki H; Okadome K; Harada K; Ishimoto T; Iwatsuki M; Iwagami S; Miyamoto Y; Yoshida N; Watanabe M; Moroishi T; Komohara Y; Sawa T; Baba H
Cancer Lett; 2022 Apr; 530():59-67. PubMed ID: 35033591
[TBL] [Abstract][Full Text] [Related]
34. Small molecule inhibitors reveal an indispensable scaffolding role of RIPK2 in NOD2 signaling.
Hrdinka M; Schlicher L; Dai B; Pinkas DM; Bufton JC; Picaud S; Ward JA; Rogers C; Suebsuwong C; Nikhar S; Cuny GD; Huber KV; Filippakopoulos P; Bullock AN; Degterev A; Gyrd-Hansen M
EMBO J; 2018 Sep; 37(17):. PubMed ID: 30026309
[TBL] [Abstract][Full Text] [Related]
35. Control of NOD2 and Rip2-dependent innate immune activation by GEF-H1.
Zhao Y; Alonso C; Ballester I; Song JH; Chang SY; Guleng B; Arihiro S; Murray PJ; Xavier R; Kobayashi KS; Reinecker HC
Inflamm Bowel Dis; 2012 Apr; 18(4):603-12. PubMed ID: 21887730
[TBL] [Abstract][Full Text] [Related]
36. Design, synthesis and evaluation of novel thieno[2,3d]pyrimidine derivatives as potent and specific RIPK2 inhibitors.
Misehe M; Šála M; Matoušová M; Hercík K; Kocek H; Chalupská D; Chaloupecká E; Hájek M; Boura E; Mertlíková-Kaiserová H; Nencka R
Bioorg Med Chem Lett; 2024 Jan; 97():129567. PubMed ID: 38008339
[TBL] [Abstract][Full Text] [Related]
37. A critical role of RICK/RIP2 polyubiquitination in Nod-induced NF-kappaB activation.
Hasegawa M; Fujimoto Y; Lucas PC; Nakano H; Fukase K; Núñez G; Inohara N
EMBO J; 2008 Jan; 27(2):373-83. PubMed ID: 18079694
[TBL] [Abstract][Full Text] [Related]
38. Activation of the nucleotide oligomerization domain signaling pathway by the non-bacterially derived xanthone drug 5'6-dimethylxanthenone-4-acetic acid (Vadimezan).
Cheng G; Sun J; Fridlender ZG; Wang LC; Ching LM; Albelda SM
J Biol Chem; 2010 Apr; 285(14):10553-62. PubMed ID: 20118240
[TBL] [Abstract][Full Text] [Related]
39. RIPK2 Dictates Insulin Responses to Tyrosine Kinase Inhibitors in Obese Male Mice.
Duggan BM; Cavallari JF; Foley KP; Barra NG; Schertzer JD
Endocrinology; 2020 Aug; 161(8):. PubMed ID: 32473019
[TBL] [Abstract][Full Text] [Related]
40. Pathogen-mediated proteolysis of the cell death regulator RIPK1 and the host defense modulator RIPK2 in human aortic endothelial cells.
Madrigal AG; Barth K; Papadopoulos G; Genco CA
PLoS Pathog; 2012; 8(6):e1002723. PubMed ID: 22685397
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
